Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus - Seite 4

Follow us on social media:
Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

###

Investor Contacts:
            [e-mail]

Media Contacts:
            Thomas Pedersen
            Carrotize PR & Communications
            [phone]
            [e-mail]

Certified Adviser:

Svensk Kapitalmarknadsgranskning AB, Email: [e-mail]. Tel: [phone]

This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 24 February 2021.

Attachment

• Allarity_PR_B117_B135 Variants Update